Higher Iron Doses in Preterm Infants Don’t Harm the Gut, Trial Finds

For years, neonatologists have navigated a difficult trade-off: preterm infants desperately need iron to support brain development and replace what is lost to routine blood draws, yet concerns about gut harm have kept recommended doses conservative. A randomized clinical trial published in the American Journal of Clinical Nutrition now challenges that caution directly, finding that tripling the standard enteral iron dose did not disrupt the gut microbiome and was actually associated with less intestinal barrier damage.

Iron Deficiency and Brain Risk in Very-Low-Birth-Weight Infants

The stakes of getting iron dosing right in the NICU are high. Preterm infants are born with lower iron stores than term babies, face rapid postnatal growth demands, and lose additional iron through the repeated phlebotomy that intensive care requires. Iron is critical for synaptogenesis, myelination, and neurotransmitter production, meaning that even a transient deficiency during a sensitive developmental window can carry lasting neurological consequences. At the same time, premature and low-birth-weight infants have substantially higher iron requirements per kilogram than their term counterparts, making supplementation not optional but essential. Current guidelines have settled on 2 mg/kg/day as a cautious standard, partly on the theoretical basis that excess luminal iron might feed pathogenic bacteria in an already vulnerable gut.

Trial Results: 6 mg/kg/day Improved Iron Status Without Microbiome Harm

The trial enrolled 151 very-low-birth-weight preterm infants, with 77 assigned to 2 mg/kg/day and 74 to 6 mg/kg/day of total enteral iron. The primary outcome was fecal microbiome composition after two weeks on supplementation, assessed through metagenomic sequencing. Across the standard measures, bacterial diversity, individual taxa abundances, virulence gene potential, signs of bacterial overgrowth, and iron-related functional genes showed no statistically significant differences between the two groups. In a subgroup of singleton births, the groups did show significant differences in how the overall bacterial community structure shifted over time, but the clinical meaning of that finding remains to be worked out. On the iron status side, the higher-dose group had a lower prevalence of iron deficiency, the expected pharmacological result. The more striking finding involved intestinal barrier function: infants in the 2 mg/kg/day group had higher post-treatment concentrations of urinary claudin-3, a protein that leaks into urine when tight junctions in the gut wall are disrupted. In other words, the lower-dose group showed more, not less, evidence of gut barrier dysfunction. Fecal calprotectin, urinary intestinal fatty acid-binding protein, adverse events, and auditory brainstem response latencies at 36 weeks postmenstrual age did not differ between groups.

Why Earlier Concerns About Iron and the Preterm Gut Persisted

The worry about luminal iron was not baseless. Because 60 to 75 percent of enteral iron in preterm infants is not absorbed and therefore remains available to intestinal bacteria, higher iron doses were theorized to promote gut dysbiosis and increase risk for late-onset sepsis or necrotizing enterocolitis. An earlier observational study by Ho TTB and colleagues in 2021 suggested that higher enteral iron was linked to greater abundances of Proteus and lower alpha diversity after two weeks, lending some support to that concern. A pilot study published in 2024 by Van Ormer and colleagues in 14 infants found no obvious iron-induced dysbiosis but could not be conclusive given its small size. The new randomized trial, with 151 participants and double-blind design, provides considerably stronger evidence that the feared microbiome disruption does not materialize at clinically relevant doses.

Methodological Strengths and Remaining Limitations

Double-blinding and randomization are the methodological moves that make this study more persuasive than the observational work before it. Randomized controlled designs are particularly important for neonatal nutrition research because confounding by illness severity, feeding type, and gestational age is otherwise difficult to control. Metagenomic sequencing, rather than 16S rRNA amplicon sequencing, provided functional gene data in addition to taxonomic profiles, enabling a more complete picture of what the microbiome was doing, not just who was there. That said, the trial has real limitations. The primary outcome window was two weeks on supplementation, a short horizon for detecting longer-term shifts. The subgroup difference in community structure among singletons suggests the microbiome picture may be more complex in certain populations. Outcome data at 36 weeks for auditory latencies, a proxy for neurodevelopmental status, showed no between-group difference, but longer follow-up would be needed to assess whether improved iron stores translate into cognitive or developmental gains. The trial is registered under ClinicalTrials.gov NCT04497012.

Rethinking Conservative Iron Dosing in the NICU

The trial's authors conclude that the gut microbiome concern does not justify keeping enteral iron at 2 mg/kg/day when iron deficiency remains common at that dose. Current recommendations for infant iron supplementation were shaped in part by the precautionary principle applied to gut health, but the emerging evidence now points in a different direction: lower doses appear to leave infants iron-deficient and, if the claudin-3 data hold up, may actually impair intestinal barrier integrity rather than protect it. These findings are consistent with a broader reassessment of conservative neonatal nutrition practices, where the risks of under-supplementation have sometimes been underweighted relative to theoretical harms. The study does not close the debate, but it shifts the burden of proof. Clinicians considering 6 mg/kg/day now have randomized evidence that the microbiome fears animating current guidelines are, at minimum, not confirmed in a well-powered trial.

Evidence rating

EMERGING — 84/100

Caveats:

• Study population is exclusively very-low-birth-weight preterm infants (<1500 g); findings may not generalize to term infants or other populations.
• Funding was not disclosed; independent replication in larger cohorts is needed before clinical guidelines change.
• The significant difference in bacterial community structure between groups was only observed in a subgroup of singletons, not the full cohort, limiting the strength of that finding.
• Primary microbiome outcome was assessed after only 2 weeks on iron; longer-term effects remain unknown.

Double-blind randomized clinical trial (n=151 preterm infants <1500 g) comparing two enteral iron doses, with primary outcome assessed by metagenomic fecal sequencing and secondary intestinal biomarkers. The trial provides evidence of association between higher dosing and improved iron status and barrier markers, but the mechanistic causal chain between iron dose, microbiome composition, and clinical outcomes remains partially established. This is the first RCT to address this specific dose comparison at scale in this population and has not yet been independently replicated.